Abstract
The existence of high cost-consuming and high rate of drug failures suggests the promotion of drug repositioning in drug discovery. Existing drug repositioning techniques mainly focus on discovering candidate drugs for a kind of disease, and are not suitable for predicting candidate drugs for an individual sample. Type 1 diabetes mellitus (T1DM) is a disorder of glucose homeostasis caused by autoimmune destruction of the pancreatic β-cell. Here, we present a novel single sample drug repositioning approach for predicting personalized candidate drugs for T1DM. Our method is based on the observation of drug-disease associations by measuring the similarities of individualized pathway aberrance induced by disease and various drugs using a Kolmogorov-Smirnov weighted Enrichment Score algorithm. Using this method, we predicted several underlying candidate drugs for T1DM. Some of them have been reported for the treatment of diabetes mellitus, and some with a current indication to treat other diseases might be repurposed to treat T1DM. This study conducts drug discovery via detecting the functional connections among disease and drug action, on a personalized or customized basis. Our framework provides a rational way for systematic personalized drug discovery of complex diseases and contributes to the future application of custom therapeutic decisions.
Conflict of interest statement: The authors declare that there is no conflict of interest that could be perceived as prejudicial to the impartiality of the reported research.
References
Ahn, T., E. Lee, N. Huh and T. Park (2014): “Personalized identification of altered pathways in cancer using accumulated normal tissue data,” Bioinformatics, 30, i422–429.10.1093/bioinformatics/btu449Search in Google Scholar PubMed PubMed Central
Ashburn, T. T. and K. B. Thor (2004): “Drug repositioning: identifying and developing new uses for existing drugs,” Nat. Rev. Drug Discov, 3, 673–683.10.1038/nrd1468Search in Google Scholar PubMed
Benjamini, Y. and Y. Hochberg (1995): “Controlling the false discovery rate: a practical and powerful approach to multiple testing,” J. R. Stat. Soc. B, 57, 289–300.10.1111/j.2517-6161.1995.tb02031.xSearch in Google Scholar
Boguski, M. S., K. D. Mandl and V. P. Sukhatme (2009): “Drug discovery. Repurposing with a difference,” Science, 324, 1394–1395.10.1126/science.1169920Search in Google Scholar PubMed
Cochrane, G., R. Akhtar, P. Aldebert, N. Althorpe, A. Baldwin, K. Bates, S. Bhattacharyya, J. Bonfield, L. Bower, P. Browne, M. Castro, T. Cox, F. Demiralp, R. Eberhardt, N. Faruque, G. Hoad, M. Jang, T. Kulikova, A. Labarga, R. Leinonen, S. Leonard, Q. Lin, R. Lopez, D. Lorenc, H. McWilliam, G. Mukherjee, F. Nardone, S. Plaister, S. Robinson, S. Sobhany, R. Vaughan, D. Wu, W. Zhu, R. Apweiler, T. Hubbard and E. Birney (2008): “Priorities for nucleotide trace, sequence and annotation data capture at the Ensembl Trace Archive and the EMBL Nucleotide Sequence Database,” Nucleic Acids Res., 36, D5–12.10.1093/nar/gkm1018Search in Google Scholar PubMed PubMed Central
Comino-Mendez, I., F. J. Gracia-Aznarez, F. Schiavi, I. Landa, L. J. Leandro-Garcia, R. Leton, E. Honrado, R. Ramos-Medina, D. Caronia, G. Pita, A. Gomez-Grana, A. A. de Cubas, L. Inglada-Perez, A. Maliszewska, E. Taschin, S. Bobisse, G. Pica, P. Loli, R. Hernandez-Lavado, J. A. Diaz, M. Gomez-Morales, A. Gonzalez-Neira, G. Roncador, C. Rodriguez-Antona, J. Benitez, M. Mannelli, G. Opocher, M. Robledo and A. Cascon (2011): “Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma,” Nat. Genet., 43, 663–667.10.1038/ng.861Search in Google Scholar PubMed
Dai, M., P. Wang, A. D. Boyd, G. Kostov, B. Athey, E. G. Jones, W. E. Bunney, R. M. Myers, T. P. Speed, H. Akil, S. J. Watson and F. Meng (2005): “Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data,” Nucleic Acids Res., 33, e175.10.1093/nar/gni179Search in Google Scholar PubMed PubMed Central
Dopazo, J. (2014): “Genomics and transcriptomics in drug discovery,” Drug Discov. Today, 19, 126–132.10.1016/j.drudis.2013.06.003Search in Google Scholar PubMed
Gautier, L., L. Cope, B. M. Bolstad and R. A. Irizarry (2004): “Affy–analysis of Affymetrix GeneChip data at the probe level,” Bioinformatics, 20, 307–315.10.1093/bioinformatics/btg405Search in Google Scholar PubMed
Glazko, G. V. and F. Emmert-Streib (2009): “Unite and conquer: univariate and multivariate approaches for finding differentially expressed gene sets,” Bioinformatics, 25, 2348–2354.10.1093/bioinformatics/btp406Search in Google Scholar PubMed PubMed Central
Hartwell, L. H., J. J. Hopfield, S. Leibler and A. W. Murray (1999): “From molecular to modular cell biology,” Nature, 402, C47–C52.10.1038/35011540Search in Google Scholar PubMed
Herold, K. C., W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin and J. A. Bluestone (2002): “Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus,” N. Engl. J. Med., 346, 1692–1698.10.1056/NEJMoa012864Search in Google Scholar PubMed
Kanehisa, M., Y. Sato, M. Kawashima, M. Furumichi and M. Tanabe (2016): “KEGG as a reference resource for gene and protein annotation,” Nucleic Acids Res., 44, D457–D462.10.1093/nar/gkv1070Search in Google Scholar PubMed PubMed Central
Keiser, M. J., V. Setola, J. J. Irwin, C. Laggner, A. I. Abbas, S. J. Hufeisen, N. H. Jensen, M. B. Kuijer, R. C. Matos, T. B. Tran, R. Whaley, R. A. Glennon, J. Hert, K. L. Thomas, D. D. Edwards, B. K. Shoichet and B. L. Roth (2009): “Predicting new molecular targets for known drugs,” Nature, 462, 175–181.10.1038/nature08506Search in Google Scholar PubMed PubMed Central
Kotelnikova, E., A. Yuryev, I. Mazo and N. Daraselia (2010): “Computational approaches for drug repositioning and combination therapy design,” J. Bioinform. Comput. Biol., 8, 593–606.10.1142/S0219720010004732Search in Google Scholar PubMed
Lamb, J., E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J. P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, S. J. Haggarty, P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander and T. R. Golub (2006): “The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease,” Science, 313, 1929–1935.10.1126/science.1132939Search in Google Scholar PubMed
Li, J., X. Zhu and J. Y. Chen (2009): “Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts,” PLoS Comput. Biol., 5, e1000450.10.1371/journal.pcbi.1000450Search in Google Scholar PubMed PubMed Central
Miller, S. A. and E. St Onge (2011): “Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus,” Expert Opin. Biol. Ther., 11, 1525–1532.10.1517/14712598.2011.610789Search in Google Scholar PubMed
Napolitano, F., F. Sirci, D. Carrella and D. di Bernardo (2016): “Drug-set enrichment analysis: a novel tool to investigate drug mode of action,” Bioinformatics, 32, 235–241.10.1093/bioinformatics/btv536Search in Google Scholar PubMed PubMed Central
Robinson, M. D. and A. Oshlack (2010): “A scaling normalization method for differential expression analysis of RNA-seq data,” Genome Biol., 11, R25.10.1186/gb-2010-11-3-r25Search in Google Scholar PubMed PubMed Central
Robinson, M. D., D. J. McCarthy and G. K. Smyth (2010): “edgeR: a Bioconductor package for differential expression analysis of digital gene expression data,” Bioinformatics, 26, 139–140.10.1093/bioinformatics/btp616Search in Google Scholar PubMed PubMed Central
Yang, L. and P. Agarwal (2011): “Systematic drug repositioning based on clinical side-effects,” PLoS One, 6, e28025.10.1371/journal.pone.0028025Search in Google Scholar PubMed PubMed Central
© 2019 Walter de Gruyter GmbH, Berlin/Boston
